Eikon Therapeutics (EIKN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Eikon Therapeutics (EIKN) is Moderate Underperform.

The composite score behind that read is -0.42, weighing +0.05 of bullish evidence against -0.42 bearish.

Eikon Therapeutics last closed at $7.54, +0.40% on the session.

Against the IVW growth benchmark the position is +0.56% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

18 graded predictions for EIKN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Eikon Therapeutics in the 97th percentile on return on equity, where 100 is best.

Eikon Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $406.78M.

StockMap tracks Eikon Therapeutics as the 194th largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Eikon Therapeutics ranks 344th of 377 in the group, against a group median of -0.21.